Skip to content

Research on the use of remazolam compound rifentanyl sober sedation for gastroscopy examination of obesity

Research on the use of remazolam compound rifentanyl sober sedation for gastroscopy examination of obesity

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111635
Enrollment
Unknown
Registered
2025-11-04
Start date
2025-11-04
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation

Interventions

CS Group (Sober and Calm):Intravenous injection of rifentanyl 0.5 µg/kg, intravenous injection of rimazolam 0.05 ~ 0.1 mg/kg after 1 min
DS Group (Deep Sedation):The anaesthetist administered remifentanil intravenously at 0.5 µg/kg. One minute later, remimazolam was administered intravenously at 0.1–0.2 mg/kg, with an infusion rate of

Sponsors

Zigong Fourth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
24 Years to 68 Years

Inclusion criteria

Inclusion criteria: A total of 140 obese patients undergoing diagnostic gastroscopy were selected, with all subjects meeting the following inclusion criteria: 1. Aged 24–68 years with American Society of Anesthesiologists (ASA) physical status score II; 2. Estimated gastroscopy procedure duration within 20 minutes; body mass index (BMI) 30–35 kg/m².

Exclusion criteria

Exclusion criteria: Patients with severe cardiovascular, neuropsychiatric or cerebrovascular diseases who are judged to be difficult to control the respiratory tract (improved Mallampati grade IV) or obstructive sleep apnea hypoventilation syndrome (OSAHS) are excluded. In addition, pregnant or lactating women, patients who are allergic to propofol, benzodiazepines or opioids, and patients who have sedation or surgical contraincontraindications that researchers believe affect their safety are excluded from the study.

Design outcomes

Primary

MeasureTime frame
The incidence of SpO2 values < 95% and < 90% in patients;

Secondary

MeasureTime frame
The incidence of successful sedation;Patient and endoscopist satisfaction scores;

Countries

China

Contacts

Public ContactLiJun

Zigong Fourth People's Hospital

mzys1986@163.com+86 158 8268 2365

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026